Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
56 hedge funds and large institutions have $58.1M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 18 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.78% less ownership
Funds ownership: 38.66% → 35.89% (-2.8%)
13% less funds holding
Funds holding: 64 → 56 (-8)
25% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 20
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
46% less capital invested
Capital invested by funds: $108M → $58.1M (-$50.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$1.52M |
| 2 |
Renaissance Technologies
New York
|
+$537K |
| 3 |
Millennium Management
New York
|
+$495K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$392K |
| 5 |
E
Ergoteles
New York
|
+$379K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.76M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.22M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$669K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$526K |
PSTX Hedge Fund Activity: Q2 2022 in Review
56 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q2 2022, worth a combined $58.1M — down 46% from $108M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PSTX and 12 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 15 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.52M. The largest seller was BlackRock, cutting an estimated $3.76M.
- 56 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q2 2022, down from 64 in Q1 2022.
- Funds reported $58.1M of Poseida Therapeutics, Inc. Common Stock stock for Q2 2022, down 46% quarter-over-quarter.
- 12 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q2 2022 and 18 closed out, a net change of -6 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q2 2022 was Laurion Capital Management, an estimated $1.52M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $3.76M sold.
Based on aggregated 13F filings for Q2 2022.